Retrophin appoints Horacio Plotkin CMO
This article was originally published in Scrip
Executive Summary
Horacio Plotkin
Horacio Plotkin
Retrophin, a biotechnology company developing treatments for Duchenne muscular dystrophy, focal segmental glomerulosclerosis and pantothenate kinase-associated neurodegeneration, has appointed Horacio Plotkin chief medical officer, effective 13 May. Prior to joining New York, US-based Retrophin, Dr Plotkin was executive medical director of clinical research at Alexion Pharmaceuticals. He will be based in Cambridge, Massachusetts where Retrophin plans to open an office for its clinical, medical, and regulatory operations.